证券代码：603883 证券简称：老百姓 公告编号：2025-035 老百姓大药房连锁股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度 的提示性公告 公司控股股东老百姓医药集团有限公司及其一致行动人陈秀兰女士保 证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。本公司董事会及全体董事保证公告内容与信息披露义务人提供 的信息一致。 一、 信息披露义务人及其一致行动人的基本信息 三、 其他说明 １、本次权益变动为股东履行此前披露的减持计划，不触及要约收购，本 次减持事项与股东此前已披露的计划、承诺一致。截至本公告披露日，本次减持 股份计划尚未实施完毕。 1.身份类别 | | √控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他 | 2.信息披露义务人信息 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | ...

格隆汇7月31日丨老百姓(603883.SH)公布，公司于2025年7月31日收到公司控股股东老百姓医药集团有 限公司的通知，其于2025年6月20日、6月23日、7月30日通过集中竞价交易和大宗交易方式合计减持公 司股份1811.07万股，占公司总股本的2.38%。控股股东老百姓医药集团有限公司及其一致行动人陈秀兰 合计持股比例由27.91%减少至25.53%，本次权益变动触及1%刻度。 ...

不到半小时，张景祖已经出现在李大娘家，并就她的病情给出诊疗意见。"张主任对病人热情周到，我 们遇到疑难杂症，总爱请教他。他几乎随叫随到，让这些行动不便的患者在家也能享受到高质量的医疗 服务。"张永军对此赞不绝口。 7月28日一早，长垣中西医结合医院古色古香的国医堂内，长垣市人大代表、主任中医师、河南省名中 医张景祖正在工作室给患者看诊。望闻问切，药香氤氲中，四诊合参已洞见症结。 今年3月底，全国基层名老中医药专家张景祖传承工作室揭牌暨拜师仪式举行，10多名青年医师拜张景 祖为师，为中医药行业注入新鲜血液。他在师训中道：学医先修德，应时刻谨记医德惟大，不可妄自菲 薄，贵利贱义。 "等吃完这几服药血糖稳下来，我给你抓个三五味药你当茶喝，既便宜又控糖降糖。"张景祖一边开方子 一边耐心跟患者交流…… 身为人大代表，张景祖常常利用坐诊、送医下乡等途径，广泛吸纳民意、汇集民智，并将群众的心声和 诉求转化为进一步改善民生、提升基层中医药服务能力等方面的意见建议。 忙忙碌碌一上午，快到午饭时间，张景祖的手机忽然响起。"李大娘最近胃口不好，头还晃得厉害，您 能来看看吗？"长垣市蒲西街道蒲光社区卫生室家庭医生张永军求助。他随访的 ...

Core Viewpoint - The article discusses the reasons behind the high savings rate among Chinese households, emphasizing that it stems from a lack of confidence in financial stability rather than wealth accumulation. Group 1: Economic Context - Chinese economist Chen Hao states that the average family asset is 3 million, and if one-third of the increased savings of 15 trillion in 2022 were used for housing and consumption, the economy could recover [1][3] - Zhang Jun from Fudan University highlights that the high savings are due to fear of unexpected expenses, not because people are wealthy [3][4] Group 2: Financial Pressures - Young people are burdened with long-term mortgage debts, making it difficult to spend freely [6] - The cost of marriage, including dowries and housing, adds significant financial pressure, especially in major cities where expenses can reach millions [6][8] - Rural farmers face unpredictable income due to weather conditions, necessitating savings for emergencies [8][10] Group 3: Employment and Education Costs - Office workers experience intense competition and job insecurity, leading to minimal disposable income after basic expenses [10][12] - Parents are compelled to save for their children's education to ensure they do not fall behind, which requires substantial financial resources [10][12] Group 4: Health and Safety Concerns - Medical expenses, even for minor ailments, can be burdensome, prompting families to save for health-related costs [10][12] - The pandemic has reinforced the importance of being prepared for emergencies, leading to increased savings as a precautionary measure [12][14] - Overall, the lack of social safety nets and support systems drives individuals to rely on personal savings for financial security [12][14]

| 11.50 | 202.40 | 17.60 | -10.61 | 民生证券股份有限公司苏州分 | 中银国际证券股份有 | | --- | --- | --- | --- | --- | --- | | | | | | 公司 | 限公司四川分公司 | | 11.40 | 200.64 | 17.60 | -10.61 | 长城证券股份有限公司总部 | 中银国际证券股份有 | | | | | | | 限公司四川分公司 | | 11.40 | 200.64 | 17.60 | -10.61 | 国金证券股份有限公司上海浦 | 中银国际证券股份有 | | | | | | 东新区芳甸路证券营业部 | 限公司四川分公司 | | 11.40 | 200.64 | 17.60 | -10.61 | 华泰证券股份有限公司广东分 公司 | 中银国际证券股份有 | | | | | | | 限公司四川分公司 | | 11.40 | 200.64 | 17.60 | -10.61 | 机构专用 | 中银国际证券股份有 | | | | | | | 限公司四川分公司 | | 11.40 | 200.64 | 17.60 | -10. ...

今日(7月30日)A股共49只个股发生大宗交易，总成交13.84亿元，其中招商银行、老百姓、恒力石化成 交额居前，成交额依次为2.42亿元、1.98亿元、1.5亿元。 机构专用席位卖出额排名：德明利(4255万元)、新强联(337.1万元)。 成交价方面，共8只股票平价成交，4只股票溢价成交，37只股票折价成交；华大基因、南大光电、温氏 股份溢价率居前，溢价率依次为22.34%、20.69%、19.97%；国瑞科技、广信科技、立高食品折价率居 前，折价率依次为30.34%、27.66%、22.77%。 机构专用席位买入额排名：老百姓(1.04亿元)、吉视传媒(6968万元)、通富微电(6292.57万元)、万达电影 (5088.73万元)、卓易信息(4812.43万元)、奥美医疗(3958.28万元)、华西证券(1468.55万元)、福赛科技 (1130.4万元)、雪祺电气(1063.92万元)、若羽臣(871.6万元)、微芯生物(800.04万元)、国瑞科技(752.34万 元)、青龙管业(601.62万元)、筑博设计(497.81万元)、浩辰软件(447.1万元)、新强联(337.1万元)、中天精 装(2 ...

Group 1 - On July 30, the company experienced a block trade of 11.2757 million shares, with a transaction value of 198 million yuan, accounting for 20.31% of the total trading volume for the day [1] - The transaction price was 17.6 yuan, which represents a discount of 10.61% compared to the market closing price of 19.69 yuan [1]

Market Overview - The pharmaceutical commercial sector increased by 1.04% on July 30, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 3615.72, up 0.17%, while the Shenzhen Component Index closed at 11203.03, down 0.77% [1] Top Performers - Huaren Health (301408) closed at 15.01, up 5.48% with a trading volume of 334,100 shares and a transaction value of 499 million [1] - Jiazhang Tang (002462) closed at 14.67, up 4.19% with a trading volume of 232,300 shares and a transaction value of 346 million [1] - Laobaixing (603883) closed at 19.69, up 2.93% with a trading volume of 398,800 shares and a transaction value of 779 million [1] - China National Pharmaceutical (600056) closed at 11.28, up 2.64% with a trading volume of 656,900 shares and a transaction value of 747 million [1] Underperformers - Renmin Tongtai (600829) closed at 8.77, down 7.20% with a trading volume of 724,400 shares and a transaction value of 651 million [2] - Saily Medical (603716) closed at 30.89, down 2.31% with a trading volume of 444,300 shares and a transaction value of 1.385 billion [2] - Runda Medical (603108) closed at 18.20, down 1.83% with a trading volume of 299,700 shares and a transaction value of 552 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 62.07 million from institutional investors, while retail investors saw a net inflow of 64.93 million [2] - Major stocks like Laobaixing and China National Pharmaceutical had significant net inflows from retail investors, despite overall sector outflows [3] Individual Stock Analysis - Laobaixing (603883) had a net inflow of 62.57 million from institutional investors, but a net outflow of 45.34 million from retail investors [3] - China National Pharmaceutical (600056) saw a net inflow of 49.86 million from institutional investors, with a net outflow of 43.44 million from retail investors [3] - Huaren Health (301408) had a net inflow of 21.02 million from institutional investors, but a net outflow of 26.49 million from retail investors [3]

Group 1 - The core viewpoint of the article highlights the recognition of the company, Lao Bai Xing Pharmacy, as it ranks 71st in the "Top 100 Online Retailers in China" and 27th in the "Top 70 Retail Channels" [1] - The total online sales of the selected companies reached 2.17 trillion yuan, reflecting a year-on-year growth of 13.6% [4] - Lao Bai Xing Pharmacy has been strengthening its new retail business, innovating channels and products, and enhancing smart management and big data analysis to quickly respond to consumer demands [4] Group 2 - The online sales revenue (including franchises) for 2024 is projected to be approximately 2.47 billion yuan, with a year-on-year growth of about 24% [4] - In the first quarter of 2025, the company's online sales revenue (including franchises) is approximately 750 million yuan, showing a year-on-year increase of 34% [4] - As of the end of the first quarter of 2025, the company has 12,474 O2O delivery service stores and 665 24-hour stores, providing a solid foundation for instant delivery services [4] Group 3 - The company is actively engaging in multi-channel and multi-scenario live streaming, with significant results in various product categories such as health supplements [4] - In the first quarter of 2025, the company's O2O and B2C sales ranked fourth and third in the market, respectively [4] - The "Lao Bai Xing Pharmacy" WeChat mini-program offers 24-hour online services, and the service system is continuously improving, with a 70% year-on-year increase in daily active users (DAU) in the mini-program, peaking over 200,000 [4] Group 4 - Looking ahead, the company plans to leverage AI applications to continuously upgrade its new retail business strategy [5] - The company aims to enhance its professional and warm pharmaceutical service capabilities, improving customer experience through a full-chain resonance of online and offline services [5] - The company is committed to contributing to health management throughout the lifecycle of its customers, supporting the initiative of a healthy China [5]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].